Skip to main content
SpringerLink
Log in

Clinical effect of CALR allele burden in patients with essential thrombocythemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790

    Article  CAS  Google Scholar 

  2. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112:141–149

    Article  CAS  Google Scholar 

  3. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F et al (2013) Somatic mutations of CALReticulin in myeloproliferative neoplasms. N Engl J Med. 369:2379–2390

    Article  CAS  Google Scholar 

  4. Bertozzi I, Bogoni G, Biagetti G, Duner E, Lombardi AM, Fabris F, Randi ML (2017) Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol. 96:1297–1302

    Article  CAS  Google Scholar 

  5. Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, Maccari C, Ramundo F, Jadoon Y, Gesullo F, Ceglie S, Paoli C, Pardanani A, De Stefano V, Tefferi A, Vannucchi AM (2021) Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1607 patients. Am J Hematol. 96:1472–1480

    Article  CAS  Google Scholar 

  6. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405

    Article  CAS  Google Scholar 

  7. Andrikovics H, Krahling T, Balassa K, Halm G, Bors A, Koszarska M, Batai A, Dolgos J, Csomor J, Egyed M, Sipos A, Remenyi P, Tordai A, Masszi T (2014) Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica. 99:1184–1190

    Article  Google Scholar 

  8. Gángó A, Mózes R, Boha Z, Kajtár B, Timár B, Király PA, Kiss R, Fésüs V, Nagy N, Demeter J, Körösmezey G, Borbényi Z, Marton I, Szőke A, Masszi T, Farkas P, Várkonyi J, Plander M, Pósfai É et al (2018) Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Leuk Res 65:42–48

    Article  Google Scholar 

  9. Cavalloni C, Rumi E, Ferretti VV, Pietra D, Roncoroni E, Bellini M, Ciboddo M, Casetti IC, Landini B, Fugazza E, Troletti D, Astori C, Cazzola M (2017) Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms. Oncotarget 8:33416–33421

    Article  Google Scholar 

  10. Cottin L, Riou J, Orvain C, Ianotto JC, Boyer F, Renard M, Truchan-Graczyk M, Murati A, Jouanneau-Courville R, Allangba O, Mansier O, Burroni B, Rousselet MC, Quintin-Roué I, Martin A, Sadot-Lebouvier S, Delneste Y, Chrétien JM, Hunault-Berger M et al (2020) Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. Br J Haematol. 188:935–944

    Article  CAS  Google Scholar 

Download references

Funding

The study was partially supported by the DOR funding of DIMED-University of Padua, Italy

Author information

Authors and Affiliations

  1. Department of Medicine-DIMED, University of Padua, Via Giustiniani 2, 35128, Padua, Italy

    Irene Bertozzi, Giacomo Biagetti, Tommaso Vezzaro, Isabella Barzon, Marco Carraro, Fabrizio Fabris & Maria Luigia Randi

Authors
  1. Irene Bertozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giacomo Biagetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tommaso Vezzaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isabella Barzon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marco Carraro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fabrizio Fabris
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Luigia Randi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

IBe and MLR designed the research study and wrote the paper; IBe also analyzed the data; and IBa performed molecular tests; GB, TV, and MC followed and collected the patients’ data. FF critically reviewed the manuscript.

Corresponding author

Correspondence to Irene Bertozzi.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bertozzi, I., Biagetti, G., Vezzaro, T. et al. Clinical effect of CALR allele burden in patients with essential thrombocythemia. Ann Hematol 101, 1345–1346 (2022). https://doi.org/10.1007/s00277-021-04717-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04717-3

Search

Navigation